ArticleBMC cancer2015

Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan.

Seung Tae Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.